320 related articles for article (PubMed ID: 23311679)
1. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel.
Gremmel T; Eslam RB; Koppensteiner R; Lang IM; Panzer S
Cardiovasc Ther; 2013 Oct; 31(5):e40-5. PubMed ID: 23311679
[TBL] [Abstract][Full Text] [Related]
2. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients.
Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Steiner S; Panzer S
Eur J Clin Invest; 2013 Jul; 43(7):689-97. PubMed ID: 23611368
[TBL] [Abstract][Full Text] [Related]
3. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Braun OO; Johnell M; Varenhorst C; James S; Brandt JT; Jakubowski JA; Winters KJ; Wallentin L; Erlinge D; Siegbahn A
Thromb Haemost; 2008 Oct; 100(4):626-33. PubMed ID: 18841285
[TBL] [Abstract][Full Text] [Related]
4. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
Gremmel T; Xhelili E; Steiner S; Koppensteiner R; Kopp CW; Panzer S
Atherosclerosis; 2014 Jan; 232(1):119-24. PubMed ID: 24401225
[TBL] [Abstract][Full Text] [Related]
5. Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Transl Res; 2013 May; 161(5):421-9. PubMed ID: 23340049
[TBL] [Abstract][Full Text] [Related]
6. Calcium-Channel Blockers Attenuate the Antiplatelet Effect of Clopidogrel.
Gremmel T; Durstberger M; Eichelberger B; Koppensteiner R; Panzer S
Cardiovasc Ther; 2015 Oct; 33(5):264-9. PubMed ID: 26014752
[TBL] [Abstract][Full Text] [Related]
7. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.
Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
Postgrad Med J; 2006 Jun; 82(968):404-10. PubMed ID: 16754711
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease.
Klinkhardt U; Bauersachs R; Adams J; Graff J; Lindhoff-Last E; Harder S
Clin Pharmacol Ther; 2003 Mar; 73(3):232-41. PubMed ID: 12621388
[TBL] [Abstract][Full Text] [Related]
9. Platelet function in clopidogrel-treated patients with acute coronary syndrome.
Sibbing D; von Beckerath O; Schömig A; Kastrati A; von Beckerath N
Blood Coagul Fibrinolysis; 2007 Jun; 18(4):335-9. PubMed ID: 17473574
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
12. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
13. Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.
Wagner H; Lood C; Borna C; Gidlöf O; Truedsson L; Brown P; Zhou C; Winters K; Jakubowski JA; Erlinge D
J Thromb Thrombolysis; 2016 Oct; 42(3):369-75. PubMed ID: 27165280
[TBL] [Abstract][Full Text] [Related]
14. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Barrera-Ramirez C; Sabaté M; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
Thromb Res; 2005; 115(1-2):101-8. PubMed ID: 15567460
[TBL] [Abstract][Full Text] [Related]
15. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin.
Dropinski J; Musial J; Jakiela B; Wegrzyn W; Sanak M; Szczeklik A
Thromb Haemost; 2005 Dec; 94(6):1300-5. PubMed ID: 16411409
[TBL] [Abstract][Full Text] [Related]
16. The Antiplatelet Effect of Clopidogrel Decreases With Patient Age.
Xhelili E; Eichelberger B; Kopp CW; Koppensteiner R; Panzer S; Gremmel T
Angiology; 2016 Nov; 67(10):902-908. PubMed ID: 26861857
[TBL] [Abstract][Full Text] [Related]
17. Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors.
Badr Eslam R; Lang IM; Koppensteiner R; Calatzis A; Panzer S; Gremmel T
Int J Cardiol; 2013 Sep; 168(1):403-6. PubMed ID: 23041015
[TBL] [Abstract][Full Text] [Related]
18. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
[TBL] [Abstract][Full Text] [Related]
19. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity.
Bonello L; Laine M; Baumstarck K; Fernandez J; Maillard L; Peyrol M; Bessereau J; Aradi D; Camilleri E; Roubille F; Piot C; Paganelli F; Camoin-Jau L; Dignat-George F
Int J Cardiol; 2013 Oct; 168(4):4244-8. PubMed ID: 23911273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
